Sciele inks Allegra deal with Sanofi-Aventis

ATLANTA Sciele Pharma has signed a three-year deal with Sanofi-Aventis to market Allegra orally disintegrating tablets and Allegra oral suspension, according to published reports.

Sciele said it would debut Allegra ODT in March 2008. It will be responsible for all sales and marketing programs associated with the products in America and will share revenues on both versions of the drug.

Allegra Oral Suspension, 30mg/5ml, is indicated for the relief of symptoms such as sneezing, runny nose, itchy nose/palate/throat, and itchy watery, red eyes associated with seasonal allergic rhinitis in children two to 11 years of age.

Allegra had sales of $110.7 million in the U.S. in 2007, according to Sanofi-Aventis.